Lessons from the Liege Acromegaly Survey (LAS)

in Endocrine Abstracts - 15 the European Congress of Endocrinology (2013, May)

GH or IGF-1 : which one is raising blood glucose ? Hints from the LAS (Liege Acromegaly Survey)

in Journal of Klinische Endokrinologie und Stoffwechsel (2012, September), 5(3),

Aging of the newly diagnosed acromegalic patients : data frome the LAS (Liege Acromegaly Survey)

in Journal für Klinische Endokrinologie und Stoffwechsel (2012, September), 5(3), 33

Clinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients

in Annales d'Endocrinologie (2012, April), 73(2), 153

Cyclin dependent kinase inhibitor (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds

in Endocrine-Related Cancer (2012), 19

Clinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients

in ENEA Munich - abstract book (2011, December)

Liège Acromegaly Survey (LAS): First snapshot

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

High Prevalence of AIP Gene Mutations Following Focussed Screening in Young Patients with Sporadic Pituitary Macroadenomas

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.

in World Journal of Surgery (2010), 34(2), 249-255

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a ... [more ▼]

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a large cohort of MEN1 patients. Methods - Overall, 758 symptomatic MEN1 patients were identified through the GTE network (Groupe d’étude des Tumeurs Endocrines), which involves French and Belgian genetics laboratories responsible for MEN1 diagnosis and 80 clinical reference centers. The causes of death were analyzed. A frailty model, including time-dependent variables, was used to assess the impact of each clinical lesion, except for hyperparathyroidism, on survival. Results - The median follow-up was 6.3 years. Female gender, family history of MEN1, and recent diagnosis were associated with a lower risk of death. Compared with nonaffected patients, those with thymic tumors (hazard ratio [HR] = 4.64, 95% CI = 1.73-12.41), glucagonomas–vipomas–somatostatinomas (HR = 4.29, 95% CI = 1.54-11.93), nonfunctioning pancreatic tumors (HR = 3.43, 95% CI = 1.71-6.88), and gastrinoma (HR = 1.89, 95% CI = 1.09-3.25) had a higher risk of death after adjustment for age, gender, and diagnosis period. The increased risk of death among patients with adrenal tumors was not significant, but three patients died from aggressive adrenal tumors. Pituitary tumors, insulinomas, and bronchial tumors did not increase the risk of death. The proportion of MEN1-related deaths decreased from 76.8 to 71.4% after 1990. Conclusions - The prognosis of MEN1 disease has improved since 1980. Thymic tumors and duodenopancreatic tumors, including nonsecreting pancreatic tumors, increased the risk of death. Rare but aggressive adrenal tumors may also cause death. Most deaths were related to MEN1. New recommendations on abdominal and thoracic imaging are required. [less ▲]

Characterization of prolatinomas resistant to dopaminergic agonists

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)